To improve early detection of cancers, blood-based biomarkers have a minimal benchmark that they must perform better by themselves or in combination with current ones [e.g., cancer antigen 125 (CA125); cancer antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA); and prostate-specific antigen (PSA)]. This evidence concerns the gene CEACAM5 and cancer.